drugset / Trial / NCT04781374
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 2
Withdrawn
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute · collabPuma Biotechnology, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is examining whether Neratinib has any activity in participants with prostate cancer that has spread and is no longer responding to hormonal treatment. \- The names of the study drug involved in this study is neratinib.
Timeline
- Start
- 2021-05-21
- Primary completion
- 2021-09-24
- Completion
- 2021-09-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neratinib | Small molecule | — | Oral |